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By definition, tumor biomarkers are selective molecules that can distinguish between patients with cancer and controls. Serum tumor markers
have been the most widely used approach for cancer detection. However, the limitations of these markers, which are based on the measurement of
tumor antigens, preclude their general use in cancer screening and diagnosis. Here we give an overview of recent cancer biomarker developments
based on the detection of autoantibodies produced against tumor antigens in patients' sera. This new detection method can measure the
autoantibodies for a spectrum of tumor antigens in a single assay, with sensitivity and specificity exceeding those obtained using the conventional
antigen determination method. Autoantibodies against serum cancer biomarkers offer a novel technology for cancer detection.
Published by Elsevier B.V.Keywords: Autoantibody-based EIA; Cancer detection; Biomarker; Autoantibody ECPKA; cAMP-dependent protein kinase1. Introduction
An ideal tumor biomarker would allow a simple blood test to
detect cancer. Due to a lack of sensitivity and specificity,
however, no single marker has been recognized as a true cancer
marker. Currently available serum biomarkers are based on the
measurement of cancer antigens [1]. For example, the prostate-
specific antigen (PSA) is measured for prostate cancer
biomarker [2], the carcinoembryonic antigen (CEA) for
colorectal cancer [3], the cancer antigen CA15-3 for breast
cancer [4], the cancer antigen CA19-9 for gastrointestinal
cancer [5], and the cancer antigen CA125 for ovarian cancer [6].
In addition to these novel markers, some other proteins,
hormones, and enzymes have been used as markers for the
past 30 years [1,7]. But these markers show limited specificity
and sensitivity, and levels also increase under benign conditions
and during gestation. There is great need to discover novel
biomarkers and translate them into routine clinical use. An
extensive literature review is not intended for this review. Only
selected reviews describe the development of a specific new
approach: “autoantibody detection in cancer diagnosis.”⁎ Tel.: +1 301 496 4020; fax: +1 301 480 8587.
E-mail address: yc12b@nih.tov.
0925-4439/$ - see front matter. Published by Elsevier B.V.
doi:10.1016/j.bbadis.2006.04.0012. Discovery of autoantibody ECPKA—a universal cancer
biomarker
In normal mammalian cells, cAMP-dependent protein kinase
A (PKA) is an intracellular enzyme [8,9]. Intriguingly, however,
in cells of various cancer types, it is secreted into the
conditioned medium [10,11]. This PKA, designated as
extracellular protein kinase A (ECPKA), is markedly up-
regulated in the serum of cancer patients [10,11], and surgical
removal of tumors leads to decreased ECPKA levels [12].
Modulation of intracellular levels of PKA type I regulates
ECPKA levels [10].
There is increasing evidence for an immune response to
cancer in humans, demonstrated in part by the identification of
autoantibodies against a number of intracellular and surface
antigens in patients with different tumor types [13–16]. Such
autoantibodies could have diagnostic and prognostic utility.
With the speculation that ECPKA excretion might elicit the
induction of serum autoantibodies and that the presence of such
autoantibodies could serve as a cancer diagnostic, a novel
enzyme immunoassay (EIA) that measures IgG autoantibody
against ECPKA was developed [17]. This autoantibody was
found to be elevated in patients with a wide range of active
cancers in various stages of malignancies in different cell types,
including bladder, breast, cervical, colon, esophageal, gastric,
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bowel, rectal, adenocystic carcinomas, melanoma, sarcoma and
thyoma, liposarcoma, and leiomyosarcoma [17].
The sera-presence of an autoantibody directed against
ECPKA was highly correlated to cancer. High anti-ECPKA
autoantibody titers (frequency=90%, mean titer=3.6) were
found in cancer patients, whereas low or negative titers
(frequency=13%, mean titer=1.0) were found in the control
group. The ROC plot showed that autoantibody EIA exhibited
90% sensitivity, and 87% specificity, whereas the enzymatic
assay (antigen determination method) exhibited 83% sensitivity
and 80% specificity. These results show that the autoantibody
detection method exhibits higher sensitivity and specificity than
the antigen determination method [17].
3. It is an all-in-one assay that screens for a spectrum of
serum biomarker autoantibodies
The known serum tumor markers might also produce
autoantibodies, as was shown for ECPKA, and the autoanti-
body-based EIA developed for ECPKA could also be used to
assay for these serum tumor marker autoantibodies, which led to
assay for the known serum tumor markers using the ECPKA
autoantibody EIA. The same serum samples were used for
determination of both the autoantibody assay and the antigen
kits. The results indicated that the single method of ECPKA
autoantibody EIA is applicable for the detection of autoanti-
bodies specific to each of 10 tumor markers [17]. The parallel
results (ROC curves almost superimposable) obtained with the
autoantibody EIA and antigen kit assays for some tumor
markers, and the superior ROC curves obtained with autoan-
tibody EIA compared to the antigen kit assays obtained for
other tumor markers, support the autoantibody EIA method
presented here as a universal screen for serum tumor markers.
4. Conclusions from these studies
(1) The data show a sensitive method for measuring IgG
autoantibodies against a spectrum of serum tumor
markers in a single assay; the method is easy to perform,
reproducible, rapid, and inexpensive (for example, one kit
instead of 10 kits) [17].
(2) The autoantibody EIA exhibits enhanced sensitivity and
specificity for the tumor markers VEGF, CA125, AFP,
and ECPKA, compared to those obtained with the antigen
kits; for CA15-3, hCG, Her-2, CEA, and CA19-9
markers, the data obtained with the autoantibody EIA
and the antigen kits are similar [17]. Results indicate that
serum tumor markers may all produce autoantibodies and
that the autoantibody EIA is a novel screening method for
cancer detection.
(3) This new assay, an autoantibody detection method, could
make it possible to distinguish between the increased
levels of tumor markers caused by cancer and those
caused by inflammation. Known cancer markers all
depend on the measurement of cancer antigens, and an
increase in such antigens can occur temporarily withinflammation, but such an increase might not increase
autoantibodies.
(4) The results indicate the probable utility of this new
autoantibody detection EIA as a cancer screening tool for
cancer diagnosis without the false positives associated
with conventional testing. It could thus provide a novel
technology for cancer detection.
5. SEREX and cancer immunomics
The use of SEREX (serological analysis of recombinant
tumor cDNA expression libraries) [18–23] led to the identifi-
cation of a large group of autoantigens in cancer patients' sera.
This emerging area of research, termed “cancer immunomics,”
allows a global analysis of the autoantibodies produced by
neoplasms against their antigens. Hundreds of autoantigens
have been cloned with recognition of antibodies in patients'
sera; however, efforts to predict malignant disease based on
autoimmunity to individual antigens have thus far been largely
unsuccessful. Although in aggregate these studies strongly
suggest that autoantibodies have potential as biomarkers, thus
far they have not resulted in serological markers with definitive
predictive ability for cancer in the clinical arena [24,25], and
none have been selected for cancer diagnosis [24,25]. One
important problem inherent to autoantibody-based methods for
identifying tumor-related antigens is demonstrating their tumor
relevance. Cited below are examples of studies showing such
relevance.
6. Autoantibody signatures in prostate cancer
The use of PSA-based screening for prostate cancer has risen
dramatically since its introduction in the late 1980s [26,27].
However, reliance on PSA for the detection of early prostate
cancer is still unsatisfactory, especially because of a high rate of
false positive results [2] as high as 80%.
This study [28] presents findings of new biomarkers:
autoantibody signatures in prostate cancer. Using protein
microarrays, autoantibodies produced by prostate tumors
against tumor antigens were identified in patients with prostate
cancer. Specifically, phage-protein microarrays were screened
to identify phage-peptide clones that bind autoantibodies in
serum samples from patients with prostate cancer but not in
those from controls. The results were consistent across a range
of clinical and pathological features, including PSA level,
Gleason grade, stage, and presence or absence of PSA
recurrence. It was concluded that autoantibodies against
peptides derived from prostate cancer tissue could be used as
the basis for improving a screening test for serum biomarkers
for prostate cancer.
7. Autoantibodies to annexin XI-A in the diagnosis of
breast cancer
Efforts to diagnose breast cancer based on autoantibodies to
the hundreds of individual antigens that have been cloned have
thus far been largely unsuccessful. Although the range of
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the literature is broad [14,29], few have been incorporated into
routine oncologic practice, and none is thought to be of value
for the diagnosis of ductal carcinoma in situ (DCIS) of the
breast.
Annexin XI is a member of the annexin superfamily of Ca2+
signal transduction proteins associated with cell growth and
differentiation.
This study [30] reports on the identification of autoantigens
commonly recognized by sera from patients with breast cancer.
They selected 10 sera from patients with invasive ductal
carcinoma (IDC) of the breast with high titer IgG autoantibodies
for biopanning of a T7 phage breast cancer DNA display library.
However, autoantigens cloned by immunoscreening cDNA
expression libraries by breast cancer patient sera are not
necessarily related to breast cancer. A number of phage inserts
cloned with sera from patients with IDC of the breast were
significantly recognized by normal control sera and not by
cancer patient sera. The significance of the presence of these
autoantibodies in the non-cancer control sera is unknown, but it
is clear that despite the origin of the cloning sera obtained from
patients with breast cancer, these autoantigens are irrelevant to
breast cancer and might be related to autoimmunity in
degenerative brain diseases or to other causes.
In view of these findings, it is likely that probing this
autoantigen microarray prospectively with sera from a large
cohort of breast cancer patients could allow the identification of
biomarkers with diagnostic significance and perhaps identifi-
cation of discrete antigen phenotypes with clinical significance.
The high prevalence of IgG autoantibodies in the sera of
patients with DCIS and IDC of the breast suggests that they are
potentially excellent candidates as biomarkers for the early
diagnosis of breast cancer.
8. Serum osteopontin determination in lung cancer
Pleural mesothelioma is an asbestos-related cancer with a
median survival of 8 to 12 months [31]. Patients with stage 1A
disease, however, can survive for five or more years if the tumor
is promptly resected. Unfortunately, it means that less than 5%
of patients with pleural mesothelioma present with stage 1A
disease. Therefore, a marker or series of biomarkers that can
predict the development of mesothelioma or detect pleural
mesothelioma in its early stages in populations with exposure to
asbestos would be of considerable value. The authors undertook
the present study [32] to test their hypothesis that osteopontin is
a useful biomarker in pleural mesothelioma and, more
specifically, to compare serum levels of osteopontin in a cohort
of subjects with asbestos-related nonmalignant disease with
preoperative levels in patients with surgically treated pleural
mesothelioma.
An analysis of serum osteopontin levels comparing the
receiver-operating-characteristic curve in the group exposed to
asbestos with that of the group with mesothelioma had a
sensitivity of 77.6% and a specificity of 85.5% at a cutoff value
of 48.3 ng of osteopontin per milliliter. Subgroup analysis
comparing patients with stage I mesothelioma with subjectswith exposure to asbestos revealed a sensitivity of 84.6% and a
specificity of 88.4% at a cutoff value of 62.4 ng of osteopontin
per milliliter. The authors concluded that serum osteopontin
levels can be used to distinguish persons with exposure to
asbestos who do not have cancer from those with exposure to
asbestos who have pleural mesothelioma [32].
It will be intriguing to question if autoantibody determina-
tion rather than antigen determination of serum osteopontin
levels could improve the early diagnosis of this deadly disease.
9. Autoantibody against p53 protein in pancreatic cancer
In addition to molecular and immunohistochemical analysis,
a serological analysis can be performed to identify p53 changes.
Antibodies against p53 protein have been detected in the serum
of patients with breast carcinoma [14], Burkitt's lymphoma
[33], and lung carcinoma [16]. Several studies have shown that
those antibodies are usually associated with the presence of a
mutant p53 protein accumulated in tumor cells.
Specific markers for pancreatic or biliary cancers have been
developed in the past few years. CA19-9 has a good sensitivity,
but it is also increased in benign cholestasis. Mutations in the
p53 gene are commonly reported in pancreatic cancer and can
be detected by a serological analysis. This study [29] shows the
presence of autoantibodies against p53 determined by EIA in
patients with pancreatic cancer, biliary tract cancer, and benign
biliary or pancreatic diseases as controls. It is concluded that the
presence of p53 antibodies in the serum of patients with
pancreatic and biliary diseases is specific for malignancy and
independent of the presence of cholestatic disease.
10. The power and failure of traditional biomarkers
Protein markers, ideally detectable in serum samples, are
most convenient for clinical routine. PSA or CEA are
biomarkers routinely used in clinical practice to predict the
presence of a tumor or therapeutic response. However, because
PSA is not tumor-specific, serum levels can increase even
during benign prostate diseases.
The “ideal” tumor marker defined for a specific cancer
should have three defining characteristics. First, the marker
should be expressed exclusively by a particular tumor. It should
only be expressed in a specific cancer and not under physiologic
conditions. Second, ease of specimen collection for the tumor
marker assay is important, ideally being a serological sample.
Assay cost could be adversely affected by more challenging
types of specimen collection. Third, the tumor marker assay
should be easy to perform, reproducible, rapid, and inexpensive.
However, such an ideal tumor marker does not yet exist for
cancer screening.
CEA is expressed in a variety of extra-intestinal tumors, such
as lung, breast, ovarian, and bladder cancers [3]. CEA has the
distinct advantage that serum levels can be determined
accurately, reproducibly, and relatively inexpensively. This led
many to believe that CEA could be used as a serological
screening tool for early colorectal cancer (CRC) detection.
Subsequent studies have demonstrated, however, that it
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this capacity [3]. It is least sensitive for stage I CRC.
Other tumor antigens that have been used as CRC markers
include tumor-associated glycoprotein-72 (TAG-72), a high
molecular weight mucin-like glycoprotein expressed in a
variety of human cancers; carbohydrate antigen CA19-9, an
oligosaccharide related to the Lewis A blood group substance;
and lipid-associated sialic acid (LASA). As with CEA, these
tumor markers show low sensitivity and specificity in CRC and
have proven ineffective as screening and diagnostic tools.
Although PSA has affected prostate cancer detection
positively, problems with specificity remain. One important
contributing factor is the fact that PSA is organ specific and not
cancer specific. Serum PSA level does not change only because
of cancer, but also with inflammation, trauma, or benign
proliferation [2]. There is considerable overlap in PSA levels
among men with prostate cancer and those with benign disease.
The discovery of new molecular forms of PSA, such as free
PSA (fPSA) and complex derivatives of PSA, offers the
potential for improved diagnostic discrimination of prostate
cancer from benign conditions [2]. Research showing the
altered serum distribution of molecular derivatives of PSA in
men with cancer and those with benign disease lends itself to
novel methods of risk stratification.
The PSA revolution that has occurred over the past two
decades has positively affected the detection and treatment of
men with prostate cancer. Although methods to improve
specificity have shown promise, meaningful interpretation has
yet to be uniformly accepted within clinical practice. The
identification of other molecular forms of PSAwithin serum has
led to a new era in PSA markers. Although the discovery of
various free forms of PSA has introduced the potential for
improved specificity in detection, further evaluation is antici-
pated. The development of improved methods to detect and
measure cPSA has the potential to replace PSA as a standard
diagnostic test in cancer screening [2].
11. Conclusion and perspective
It is evident that a wide variety of tumor markers exists with
the potential for clinical use in cancer diagnosis and for the
determination of postoperative prognosis and response to
treatment in cases of metastatic disease. Each tumor marker,
however, has limitations, and none is ideal.
The identification of circulating tumor antigens or their
related autoantibodies provides a means for early cancer
diagnosis as well as a lead for therapy. A test based on the
demonstration of autoantibodies to tumor antigens in sera of
patients could be of great importance for early detection of
cancer because of the prolonged time course of carcinogenesis
and because a detectable level of antibodies against carcinogen
stimulus could form well before the tumor phenotype arises.
This review highlights the development of a new biomarker
that screens cancers of various cell types. Because autoanti-
bodies for cancer antigens have never been carefully examined
and because the current cancer biomarker detection methodol-
ogies that are based on tumor antigen measurement have failedto detect cancers, the autoantibody measurement against the
new biomarker, ECPKA was developed.
The anti-ECPKA autoantibody, whose presence has been
highly correlated to cancer [17], measures malignant transfor-
mation in all cells and is not specific to one type of cancer.
Unlike tests such as CEA, which measures less well-defined
antigens and whose serum levels tend to be inconsistent but
elevated late in the disease [3], the anti-ECPKA autoantibody
test measures the autoantibody of a well-defined cancer antigen,
ECPKA, whose serum levels are specifically up-regulated in
cancer patients' sera and are regulated by the intracellular levels
of PKA-I [10].
Because an increase in PKA-I expression has been shown to
occur at the very early phase of carcinogenesis, well before the
tumor phenotype manifests [34], it is probable that the ECPKA-
autoantibody detection in patients' sera could serve as an early
diagnostic method for cancers of various cell types.
Most importantly, this new assay, the ECPKA autoantibody
assay, could be used as a universal screening method to detect
serum tumor markers. The detection of autoantibodies for a
spectrum of serum tumor markers, demonstrated in an all-in-one
assay [17], suggests that this new assay, the autoantibody
screening method, might facilitate the accurate and early
detection of cancer.
Whether ECPKA-autoantibody expression could be affected
by any temporal physiological or pathological conditions other
than cancer remains to be established. Ideally, biomarkers
should fulfill several key requirements: they should be easy to
measure using standardized and inexpensive methods, they
should be expressed in accessible material (e.g., cells and body
fluids), they should have a clearly defined cutoff value (which
might differ between different patient strata), and they should
have high predictive power (high sensitivity and specificity).
The autoantibody-based EIA method presented here shows its
utility as a routine diagnostic procedure to detect cancer of
various cell types by measuring various serum tumor biomar-
kers in a single assay. Thus, the autoantibody biomarker-
detecting EIA is better than antigen-determining EIA kits in
saving time for diagnosis and costs imposed on patients for
these diagnostic kits. This new assay, detection of autoanti-
bodies against serum cancer biomarkers rather than measuring
tumor antigens, offers a novel technology for cancer detection.
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